Skip to main content
Login
Contact
Subscribe
Search form
Search
The Borger News-Herald
Home
Forms
News
Sports
Obituaries
Classifieds
Place an Ad
Classified Display Ads
Service Directory
Photos
Videos
Games
Entertainment
Calendar
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Curis Inc
(NQ:
CRIS
)
11.50
USD
-0.33 (-2.79%)
Official Closing Price
Updated: 7:54 PM EDT, Apr 9, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Curis Inc
< Previous
1
2
3
Next >
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
April 07, 2021
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on April 1, 2021, the independent...
From
PR Newswire
Curis to Present at 20th Annual Needham Virtual Healthcare Conference
April 06, 2021
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive...
From
PR Newswire
Curis Reports Fourth Quarter and Year-End 2020 Financial Results
March 16, 2021
- Significantly expanded IRAK4 inhibitor CA-4948 development to include Phase 1 CA-4948 monotherapy study in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), Phase 1 CA-4948/ibrutinib...
From
PR Newswire
Curis Announces Abstract for CA-4948 Accepted for Presentation at the American Association for Cancer Research Annual Meeting
March 10, 2021
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that an abstract for CA-4948, a small molecule...
From
PR Newswire
Curis to Release Fourth Quarter 2020 Financial Results and Hold Conference Call on March 16, 2021
March 09, 2021
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its fourth quarter...
From
PR Newswire
Curis to Present at H.C. Wainwright & Co. Global Life Sciences Conference
March 02, 2021
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive...
From
PR Newswire
Curis to Present at SVB Leerink 10th Annual Global Healthcare Conference
February 19, 2021
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive...
From
PR Newswire
Curis Doses First Patient in Phase 1 Study of CA-4948 in Combination with Ibrutinib in Patients with Relapsed or Refractory Hematologic Malignancies
February 09, 2021
- Amends existing protocol of ongoing Phase 1 study in R/R NHL -
From
PR Newswire
Curis Announces Initiation of Investigator-Sponsored Phase 2 LUCAS Study of CA-4948 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate-Risk Myelodysplastic Syndromes
February 02, 2021
- Phase 2 study sponsored by investigators at Universität Leipzig in Germany -
From
PR Newswire
Thinking about buying stock in GameStop, AMC Entertainment, Novavax, Riot Blockchain, or Curis?
January 29, 2021
InvestorsObserver issues critical PriceWatch Alerts for GME, AMC, NVAX, RIOT, and CRIS.
From
PR Newswire
Curis to Present at B. Riley Securities Virtual Oncology Investor Conference
January 14, 2021
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive...
From
PR Newswire
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
January 08, 2021
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on January 4, 2021, the independent...
From
PR Newswire
Curis to Present at H.C. Wainwright & Co. Bioconnect 2021 Virtual Conference
January 05, 2021
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive...
From
PR Newswire
CytomX Therapeutics Appoints Dr. Mani Mohindru to Board of Directors
December 22, 2020
From
GlobeNewswire News Releases
Small Cap Momentum Stories to Watch (NASDAQ: BLNK) (OTC US: MMEDF) (OTC US: CLKA) (NASDAQ: CRIS)
December 16, 2020
Tags
Small Business
Environment
Shareholders
From
OTC
SAB Biotherapeutics Announces New Appointments to its Board of Directors
December 16, 2020
SAB Biotherapeutics Announces New Appointments to its Board of Directors
From
Business Wire News Releases
Curis Announces Closing of Public Offering of Common Stock with $169.6 Million in Gross Proceeds, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
December 14, 2020
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the closing of its underwritten public offering of...
From
PR Newswire
Curis Announces Pricing of Public Offering of Common Stock
December 09, 2020
Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the pricing of an underwritten public offering of...
From
PR Newswire
Thinking about buying stock in Rocket Pharmaceuticals, Sorrento Therapeutics, Intec Pharma, Cinedigm Corp, or Curis Inc?
December 09, 2020
InvestorsObserver issues critical PriceWatch Alerts for RCKT, SRNE, NTEC, CIDM, and CRIS.
From
PR Newswire
Curis Announces Proposed Public Offering of Common Stock
December 08, 2020
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced its intention to offer and sell shares of its...
From
PR Newswire
Thinking about buying stock in Curis, Blink Charging, BioCryst Pharmaceuticals, Electrameccanica Vehicles, or Uranium Energy?
December 08, 2020
InvestorsObserver issues critical PriceWatch Alerts for CRIS, BLNK, BCRX, SOLO, and UEC.
From
PR Newswire
Curis Announces Positive Preliminary Data from Ongoing Phase 1 Study of CA-4948 Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes
December 08, 2020
- Reduction of marrow blasts observed in all evaluable patients -
From
PR Newswire
Curis Announces Updated Preliminary Data from Ongoing Phase 1 Study of CA-4948 Showing Durable and Dose-Dependent Reductions in Tumor Burden in Patients with Relapsed or Refractory Non-Hodgkin's Lymph
December 07, 2020
- Tumor reductions observed in 6 of 7 patients treated at 300 mg BID following median 4 prior lines of therapy -
From
PR Newswire
Curis to Host Virtual Event to Discuss CA-4948 Clinical Data
December 02, 2020
- KOL Event featuring Dr. Amit Verma scheduled for Tuesday, December 8 at 8:00 a.m. ET -
From
PR Newswire
Curis Reports Third Quarter 2020 Financial Results
November 10, 2020
- Clinical data in CA-4948 NHL and AML/MDS trials to be presented in oral presentation and poster sessions at ASH -
From
PR Newswire
Curis Announces Collaboration with the National Cancer Institute for the Development of IRAK4 Inhibitor, CA-4948, as an Anti-Cancer Agent
November 10, 2020
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it has entered into a Cooperative Research...
From
PR Newswire
Curis Announces Three Abstracts for CA-4948 Accepted for Presentation at the 62nd American Society of Hematology Annual Meeting and Exposition
November 04, 2020
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that three abstracts for CA-4948, a small molecule...
From
PR Newswire
Curis to Present at H.C. Wainwright & Co. 6th Annual Israel Conference
November 04, 2020
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive...
From
PR Newswire
Curis to Release Third Quarter 2020 Financial Results and Hold Conference Call on November 10, 2020
November 02, 2020
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its third quarter...
From
PR Newswire
Curis Highlights Publication in ACS Medicinal Chemistry Letters Showcasing Targeted Potency and Ideal Pharmacologic Properties of CA-4948 for Treatment of Hematologic Malignancies
October 21, 2020
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today highlighted a paper published online in ACS Medicinal...
From
PR Newswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.